

**Tepotinib**

VISION

## PRELIMINARY SCORE

## CURATIVE



## NON-CURATIVE



## ADJUSTMENTS

## Quality of life



## Serious and disabling adverse effects



## Other adjustments



## FINAL SCORE

## CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

## NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

## INFORMATION

Tumour type: Thoracic Malignancies

Therapeutic Indication: EMA: Treatment for patients with NSCLC harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping following prior treatment with immunotherapy and/or platinum-based ChT. FDA: For adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.

Experimental Arm: Tepotinib

Control Arm: Single arm

